$SURF
Surface Oncology Inc
PRICE
$1.76 โฒ5.389%
Last Close
VOLUME
347,766
DAY RANGE
1.7012 - 1.805
52 WEEK
1.37 - 8.38
Key Metrics
Market Cap
96.11 M
Beta
1.38
Avg. Volume
0.95 M
Shares Outstanding
54.61 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
CEO: J. Jeffrey Goater
Website: www.surfaceoncology.com
HQ: 50 Hampshire St Fl 8 Cambridge, 02139-1548 Massachusetts
Related News